Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Emilia Myrup Thiesson"'
Autor:
Anders Hviid, Niklas Worm Andersson, Rickard Ljung, Emilia Myrup Thiesson, Nicklas Pihlström, Kristýna Faksová, Eero Poukka, Linda Gough, Jori Perälä, Mie Agermose Gram, Tuija Leino
Publikováno v:
BMJ Medicine, Vol 3, Iss 1 (2024)
Objective To estimate the effectiveness of vaccination with a monovalent covid-19 mRNA vaccine containing the omicron XBB.1.5 subvariant against severe covid-19 disease in Denmark, Finland, and Sweden.Design Target trial emulation based on registry d
Externí odkaz:
https://doaj.org/article/e6b9c4b1e63f41faa18b07f4971dc032
Autor:
Thorbjørn Søren Rønn Jensen, Emilia Myrup Thiesson, Kåre Fugleholm, Jan Wohlfahrt, Tina Nørgaard Munch
Publikováno v:
Brain and Spine, Vol 3, Iss , Pp 101889- (2023)
Externí odkaz:
https://doaj.org/article/12de48ab92e84b4eb453478e5714e4fb
Autor:
Niklas Worm Andersson, Emilia Myrup Thiesson, Ria Lassaunière, Jørgen Vinsløv Hansen, Anders Hviid
Reports suggest that the potential long-lasting health consequences of SARS-CoV-2 infection may involve persistent dysregulation of some immune populations, but the potential clinical implications are unknown. In a nationwide cohort of 2,430,694 50+-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::404247b583d288c1d516cb83ff32d269
https://doi.org/10.1101/2023.04.03.23288102
https://doi.org/10.1101/2023.04.03.23288102
Publikováno v:
Annals of Internal Medicine. 175:541-546
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b5e5d1f04c88becebe375d8ee4ecc54
https://doi.org/10.7326/m21-2452
https://doi.org/10.7326/m21-2452
BackgroundSafety data to support bivalent omicron-containing mRNA-booster vaccination are lacking.MethodsIn a Danish nationwide cohort study from 1 January 2021 to 10 December 2022, we examined the association between bivalent omicron-containing mRNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c98bc19c58cc0188e99d1625ad3caf8c
https://doi.org/10.1101/2023.01.21.23284855
https://doi.org/10.1101/2023.01.21.23284855
Autor:
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, Eero Poukka, Hinta Meijerink, Rickard Ljung, Anders Hviid
BackgroundData on the comparative vaccine effectiveness (CVE) of the bivalent mRNA-booster vaccines containing the original SARS-CoV-2 and omicron BA.4-5 and BA.1 subvariants are limited.MethodsIn a period of BA.4-5 subvariants predominance, we estim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a327c47776129f8d1373276f9213c9d7
https://doi.org/10.1101/2023.01.19.23284764
https://doi.org/10.1101/2023.01.19.23284764
Autor:
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, Eero Poukka, Lars Christian Lund, Christian Holm Hansen, Mia Aakjær, Jesper Kjær, Catherine Cohet, Mathijs Goossens, Morten Andersen, Jesper Hallas, Hinta Meijerink, Rickard Ljung, Anders Hviid
ObjectiveTo investigate the effectiveness of heterologous booster schedules with AZD1222 (Oxford-AstraZeneca, referred to as AZD), BNT162b2 (Pfizer-BioNTech, BNT), and mRNA-1273 (Moderna, MOD) vaccines compared with primary schedules and with homolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bceebbd9fdd1f40e80969631b9930d73
https://doi.org/10.1101/2022.11.24.22282651
https://doi.org/10.1101/2022.11.24.22282651
Autor:
Niklas Worm Andersson, Emilia Myrup Thiesson, Mona Vestergaard Laursen, Stine Hasling Mogensen, Jesper Kjær, Anders Hviid
Publikováno v:
Andersson, N W, Thiesson, E M, Laursen, M V, Mogensen, S H, Kjær, J & Hviid, A 2022, ' Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines : nationwide cohort study ', The BMJ, vol. 378, e070483 . https://doi.org/10.1136/bmj-2022-070483
ObjectiveTo assess the risk of adverse events associated with heterologous primary (two dose) and booster (three dose) vaccine schedules for covid-19 with Oxford-AstraZeneca’s ChAdOx1-S priming followed by mRNA vaccines (Pfizer-BioNTech’s BNT162b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd5a9679eda91cef1082ac26ddb7deeb
https://pubmed.ncbi.nlm.nih.gov/35831006
https://pubmed.ncbi.nlm.nih.gov/35831006
Publikováno v:
Hoffmann, S S, Thiesson, E M, Johansen, J D & Hviid, A 2022, ' Risk factors for granulomas in children following immunization with aluminium-adsorbed vaccines : A Danish population-based cohort study ', Contact Dermatitis, vol. 87, no. 5, pp. 430-438 . https://doi.org/10.1111/cod.14180
Background: Aluminium-adsorbed vaccines may in some children cause severely itching nodules at the injection site, known as vaccination granulomas. Objective: To investigate vaccine-, child- and maternal-level risk factors for the development of vacc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::354408c99f2e7b6d10e51ad87145c6a0
https://curis.ku.dk/ws/files/319527192/AASA_Contact_Dermatitis_2022_Skovbo_Hoffmann_Risk_factors_for_granulomas_in_children_following_immunisation_with_aluminium.pdf
https://curis.ku.dk/ws/files/319527192/AASA_Contact_Dermatitis_2022_Skovbo_Hoffmann_Risk_factors_for_granulomas_in_children_following_immunisation_with_aluminium.pdf
Autor:
Jacob Dag Berild, Vilde Bergstad Larsen, Emilia Myrup Thiesson, Toni Lehtonen, Mari Grøsland, Jon Helgeland, Jan Wolhlfahrt, Jørgen Vinsløv Hansen, Arto A. Palmu, Anders Hviid
Publikováno v:
Dag Berild, J, Bergstad Larsen, V, Myrup Thiesson, E, Lehtonen, T, Grøsland, M, Helgeland, J, Wolhlfahrt, J, Vinsløv Hansen, J, Palmu, A A & Hviid, A 2022, ' Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries ', JAMA network open, vol. 5, no. 6, E2217375 . https://doi.org/10.1001/jamanetworkopen.2022.17375
JAMA Network Open
JAMA Network Open
Importance: Vaccinations are paramount to halt the COVID-19 pandemic, and safety data are essential to determine the risk-benefit ratio of each COVID-19 vaccine. Objective: To evaluate the association between the AZD1222, BNT162b2, and mRNA-1273 vacc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46e1dc68fc1640cdf535a59f1289044
https://curis.ku.dk/ws/files/315250395/dag_berild_2022_oi_220506_1654628746.57678.pdf
https://curis.ku.dk/ws/files/315250395/dag_berild_2022_oi_220506_1654628746.57678.pdf